<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582607</url>
  </required_header>
  <id_info>
    <org_study_id>3089</org_study_id>
    <nct_id>NCT01582607</nct_id>
  </id_info>
  <brief_title>Subarachnoid Administration of Levobupivacaine for Cesarean Section</brief_title>
  <official_title>Intrathecal Plain Bupivacaine, Ropivacaine and Levo-bupivacaine With or Without Fentanyl for Elective c Section.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the investigators study is to compare the clinical effects and side-effects of
      these three local anaesthetics as sole agents or with the supplementation with fentanyl for
      c-section, especially when administered in doses achieving approximately an ED 50.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrathecal (i.t.) administration of isobaric bupivacaine, ropivacaine and levobupivacaine
      with or without addition of fentanyl for c-section do not exist to date .

      Parturients scheduled for elective caesarean section will be allocated to receive
      double-blindly i.t. isobaric bupivacaine 10 mg, ropivacaine 15mg , levobupivacaine 10mg or
      the same local anaesthetics with 10 μg fentanyl respectively. Sensory block (pin prick test)
      and motor block (Bromage scale) profile, intraoperative and postoperative analgesia,
      haemodynamics and side effects will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensory block</measure>
    <time_frame>up to 150 minutes average</time_frame>
    <description>sensory block (pin prick test): every 1 min until 30min, every 5 min until 60min. every 10 min until regression to O1 (average 150 minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motor block</measure>
    <time_frame>up to 150 minutes</time_frame>
    <description>Motor block (Bromage scale): every 1 min until 30min, every 5 min until 60min. every 10 min until complete recovery of motor function (average 150 minutes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics profile (arterial pressure. heart rate)</measure>
    <time_frame>up to 150 minutes average</time_frame>
    <description>Measurement of arterial pressure and heart rate every 1 min for the first 30 min, every 5 min until 60 min, every 10 min until regression of sensory or motor block(average 150 minutes)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Stillborn Caesarean Section</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group RF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group BF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LBF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine plain</intervention_name>
    <description>2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Marcaine Spinal 5 mg/ml, AstraZeneca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine plain</intervention_name>
    <description>2.0 ml (15mg) plain ropivacaine 0.75% intrathecally</description>
    <arm_group_label>Group R</arm_group_label>
    <other_name>Naropeine 7.5mg/ml, AstraZeneca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine plain</intervention_name>
    <description>2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally</description>
    <arm_group_label>Group LB</arm_group_label>
    <other_name>Chirocaine 5mg/ml, Abbott Laboratories</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine plain +fentanyl</intervention_name>
    <description>2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally</description>
    <arm_group_label>Group BF</arm_group_label>
    <other_name>Marcaine Spinal 5 mg/ml</other_name>
    <other_name>Fentanyl, 50μg/ml, Janssen-Cilag, Belgium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine plain +. fentanyl</intervention_name>
    <description>2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally</description>
    <arm_group_label>Group RF</arm_group_label>
    <other_name>Naropeine 7.5mg/ml, AstraZeneca</other_name>
    <other_name>Fentanyl, 50μg/ml, Janssen-Cilag, Belgium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine plain +fentanyl</intervention_name>
    <description>2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally</description>
    <arm_group_label>Group LBF</arm_group_label>
    <other_name>Chirocaine 5mg/ml, Abbott laboratories</other_name>
    <other_name>Fentanyl, 50μg/ml, Janssen-Cilag, Belgium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parturients scheduled for elective c section

          -  Stillborn

          -  Normal cardiotocogram

        Exclusion Criteria:

          -  BMI&gt;35kg/m2

          -  Height &lt;150cm or &gt;185cm

          -  Age (&lt;18, &gt;40)

          -  ASA &gt; II

          -  Multiple gestation

          -  Pregnancy complications (eclampsia, GDP, placenta previa, &gt;2 previous c section)

          -  Contraindication to spinal anaesthesia

          -  Failure to educate the patient, language barrier

          -  Patient preferred GA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaos G Flaris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kriton S Filos, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kriton S Filos, Professor</last_name>
    <phone>2610999341</phone>
    <phone_ext>0030</phone_ext>
    <email>kritonfilos@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Patras, Department of Anesthesiology</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kriton S Filos, Professor</last_name>
      <phone>+302610999341</phone>
      <email>kritonfilos@yahoo.gr</email>
    </contact>
    <contact_backup>
      <last_name>Nikolaos G Flaris, MD</last_name>
      <phone>+306936622601</phone>
      <email>nflaris@yahoo.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Nikolaos G Flaris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Nikolaos G. Flaris</investigator_full_name>
    <investigator_title>Anesthesiologist,MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

